Company profile: Contineum Therapeutics
1.1 - Company Overview
Company description
- Provider of novel oral small molecule therapies for neuroscience, inflammation, and immunology, including PIPE-791, an LPA1R antagonist in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PMS); PIPE-307, a selective M1 receptor inhibitor in development for relapsing-remitting multiple sclerosis (RRMS) and depression; and LPA1R DC, a peripherally restricted LPA1R antagonist.
Products and services
- LPA1R DC: Peripherally‑restricted LPA1R antagonist aimed at expanding clinical indications involving LPA1R antagonism by leveraging its peripherally‑restricted profile
- PIPE-307: Selective M1R inhibitor that modulates muscarinic type 1 receptor activity, in development for relapsing‑remitting multiple sclerosis and depression
- PIPE-791: Small‑molecule LPA1R antagonist that targets lysophosphatidic acid 1 signaling, in development for idiopathic pulmonary fibrosis and progressive multiple sclerosis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Contineum Therapeutics
Anavex Life Sciences
HQ: United States
Website
- Description: Provider of biopharmaceutical drug candidates for cancer and neurological diseases, including ANAVEX 2-73 (blarcamesine), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) for Alzheimer's, Parkinson's, and Rett syndrome; ANAVEX 3-71 targeting sigma-1 and M1 muscarinic receptors for schizophrenia, Alzheimer's, and frontotemporal dementia; and the SIGMACEPTOR Discovery Platform for CNS disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anavex Life Sciences company profile →
Inscopix
HQ: United States
Website
- Description: Provider of neural activity imaging solutions for freely behaving subjects, enabling links between circuit dynamics and behavior. Offers the nVue dual-color system with expanded storage for longitudinal studies, the LScape module for wider field of view and longer working distance in cortical imaging, and Multicolor Data Processing software for streamlined miniscope analysis with PCA/ICA or CNMFe, filtering, and longitudinal registration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inscopix company profile →
Synaptive Medical
HQ: Canada
Website
- Description: Provider of neurosurgery, medical imaging and surgical navigation solutions, including the Synaptive Integrated Suite to integrate information and automation across interventions; Modus X robotic exoscope with 4K 3D and fluorescence visualization; Modus Plan automatic tractography segmentation; Modus Nav instrument tracking via intraoperative tractography; Synaptive MRI point-of-care MRI; ImageDrive zero-footprint HTML5 viewer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synaptive Medical company profile →
Flex Pharma
HQ: United States
Website
- Description: Provider of clinically proven products and treatments for muscle cramps and spasms, including FLX-787, a treatment in development aimed at reducing cramps and spasms by targeting hyperexcitable neurons in patients with neurological disorders; HOTSHOT, a consumer product for athletes designed to prevent and treat cramps by stimulating TRP ion channels; and R&D of treatments for cramps associated with ALS, MS, and peripheral neuropathies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Flex Pharma company profile →
Levicept
HQ: United Kingdom
Website
- Description: Provider of biological therapies for chronic pain, including LEVI-04 (p75NTR-Fc) for knee osteoarthritis that modulates the neurotrophin pathway to minimize side effects associated with anti-NGF antibodies, and a Phase II randomized, double-blind, placebo-controlled clinical trial assessing its efficacy, safety, and tolerability.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Levicept company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Contineum Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Contineum Therapeutics
2.2 - Growth funds investing in similar companies to Contineum Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Contineum Therapeutics
4.2 - Public trading comparable groups for Contineum Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →